Early studies implicated that IL-6 is a multifunctional cytokine produced during inflammation; inhibiting the IL-6/STAT3 signaling pathway may be a potential therapeutic target for IBD (Matsumoto et al., 2009). Here, IL6 is linked to irritable bowel syndrome.